WO2011034582A2 - Anticorps anti-vih-1 - Google Patents
Anticorps anti-vih-1 Download PDFInfo
- Publication number
- WO2011034582A2 WO2011034582A2 PCT/US2010/002515 US2010002515W WO2011034582A2 WO 2011034582 A2 WO2011034582 A2 WO 2011034582A2 US 2010002515 W US2010002515 W US 2010002515W WO 2011034582 A2 WO2011034582 A2 WO 2011034582A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- antibodies
- hiv
- infection
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 36
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 25
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract description 23
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 11
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims abstract description 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 abstract description 16
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 10
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 238000004113 cell culture Methods 0.000 abstract description 4
- 238000009877 rendering Methods 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 238000006386 neutralization reaction Methods 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 14
- 238000004091 panning Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 210000004602 germ cell Anatomy 0.000 description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
- 101150117115 V gene Proteins 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000031886 HIV Infections Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 206010000807 Acute HIV infection Diseases 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241001112090 Pseudovirus Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000000423 heterosexual effect Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002064 post-exposure prophylaxis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000003737 Bright-Glo Luciferase Assay System Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 description 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MUJOIMFVNIBMKC-UHFFFAOYSA-N fludioxonil Chemical compound C=12OC(F)(F)OC2=CC=CC=1C1=CNC=C1C#N MUJOIMFVNIBMKC-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000012056 up-stream process Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates, in general, to HIV-1 specific antibodies and, in particular, to broadly neutralizing HIV-1 specific antibodies that target the gp41 membrane-proximal external region (MPER).
- MPER membrane-proximal external region
- the present invention also relates to a cell culture system, more specifically, to a method of rendering chronic lymphocytic leukemia B-cells immortal and to a method of isolating anti-viral antibodies from clones of such cells.
- mAbs monoclonal antibodies against gpl 60 have been isolated that can broadly neutralize HIV-1 in vitro, and can protect non-human primates from SHIV infections in vivo (Mascola et al, Nat. Med. 6:207-210 (2000), Baba et al, Nat. Med. 6:200-206 (2000)). These mAbs include antibodies 2F5 and 4E10 against the membrane proximal external region (MPER) of gp41 (Muster et al, J. Virol. 67:6642-6647 (1 93), Stiegler et al, AIDS Res. & Hum. Retro.
- MPER membrane proximal external region
- HIV-1 has evolved a number of effective strategies for evasion from neutralizing antibodies, including glycan shielding of neutralizing epitopes (Wei et al, Nature 422:307-312 (2003)), entropic barriers to neutralizing antibody binding (Kwong et al, Nature 420:678-682 (2002)), and masking or diversion of antibody responses by non-neutralizing antibodies (Alam et al, J. Virol. 82: 1 15- 125 (2008)). Despite intense investigation, it remains a conundrum why broadly neutralizing antibodies against either the gpl 20 CD4 binding site or the membrane proximal region of gp41 are not routinely induced in either animals or man.
- the mAb 2G12 is against carbohydrates that are synthesized and modified by host glycosyltransferases and are, therefore, likely recognized as self carbohydrates (Calarese et al, Proc. Natl. Acad. Sci. USA 102: 13372-13377 (2005)). 2G12 is also a unique antibody with Fabs that assemble into an interlocked VH domain-swapped dimers (Calarese et al, Science 300:2065-2071
- 2F5 and 4E 10 both have long CDR3 loops, and react with multiple host antigens including host lipids (Zwick et al, J. Virol. 75: 10892-10905 (2001), Alam et al, J. Immun. 178:4424-4435 (2007), Zwick et al, J. Virol. 78:3155-3161
- IgG lbl 2 also has a long CDR3 loop and reacts with dsD A (Haynes et al, Science 308: 1906-1908 (2005), Saphire et al, Science 293 : 1 155-1 159 (2001)).
- the present invention results, at least in part, from studies designed to identify 2F5-like mAbs from the patient of Shen et al (J. Virol. 83:3617-25 (2009)) that confer broad neutralizing activity. These studies involved preparing libraries from antibody fragments (scFv, scFab, Fab) displayed on yeast or phage from peripheral blood mononuclear cells (PBMCs) from an HIV-1 infected individual. The libraries were panned and screened with a peptide containing the 2F5 epitope, as well as with gpl40s. Antibodies were identified that bind specifically to the peptide, that binding being competed with 2F5.
- PBMCs peripheral blood mononuclear cells
- the present invention relates to HIV-1 specific antibodies. More specifically, the invention relates to broadly neutralizing HIV-1 specific antibodies that target the gp41 MPER, and to methods of using same to both treat and prevent HIV-1 infection. The invention also relates to a method of rendering chronic lymphocytic leukemia B-cells immortal and to a method of isolating antiviral antibodies from clones of such cells.
- Figure 1 Chronic HIV-1 infections in patients with high levels of bnAbS. Antibodies in peripheral blood from a patient (SC44) with 2F5-like antibodies.
- FIGS. 4A and 4B IMGT V-Quest analysis of m66 VH and VL.
- the closet germline V gene segment is aligned with the VH as shown in Fig. 4A and VL as shown in Fig. 4B.
- the mutation sites differentiated from germline sequences were highlighted in bold font; the frameworks and CDRs also were defined and labeled according to IMGT database.
- FIGS. 5A and 5B Comparison of m66.6 and 2F5 on binding to both the MPER peptide and JRFL gpl 40 protein through ELISA.
- FIG. 5A Biotinylated MPER peptide was captured by coated strepatavidin on plate as target for the binding assay.
- FIG. 5B Purified soluble gpl40 protein was coated directly on plate as target for binding assay.
- FIG. 7 Phylogenetic tree of m66 variants.
- Figure 8. Epstein-Barr virus (EBV) transformation of B cells (for B-CLL cells).
- EBV Epstein-Barr virus
- Figure 9. Preparation of complete medium.
- Figure 10. Electro fusion procedure.
- FIG. 1 EBV-transformation of B-CLL cells and production of monoclonal antibodies.
- FIGS 12A-12D Comprehensive CLL screening results.
- the J774A.1 feeder cells enhance growth and production of IgM from B-CLL cells (CLL246) after Epstein Barr virus (EBV) infection. After incubation with EBV, the B-CLL cells were plated at 5,000 cells/well (A) in the absence of J774A.1 cells or (B) in the presence of irradiated J774A.1 cells (50,000 cells/well). Three weeks after infection, levels of IgM were detected by ELISA and expressed in ⁇ g/ml.
- FIG. 15 A B-CLL cell line, CLL246, produces IgM against both HIV-1 gpl 40 and hepatitis virus C E2 (HCV E2) envelope proteins. IgM against the test antigens was detected by ELISA and expressed in OD.
- the present invention relates, in one embodiment, to a method of inhibiting infection of cells (e.g., T-cells) of a subject by HIV-1.
- the invention also relates to a method of controlling the initial viral load and preserving the CD4+ T cell pool and preventing CD4+ T cell destruction.
- the method comprises administering to the subject (e.g., a human subject) an HIV-1 specific antibody (other than 2F5) that binds the 2F5 epitope, or fragment thereof, in an amount and under conditions such that the antibody, or fragment thereof, inhibits infection.
- the antibodies can be administered prior to contact of the subject or the subject's immune system/cells with HIV-1 or after infection of vulnerable cells. Administration prior to contact or shortly thereafter can maximize inhibition of infection of vulnerable cells of the subject (e.g., T-cells).
- One preferred antibody for use in the invention is a mAb having the variable heavy and variable light sequences of the M66 antibody as set forth in Table 1.
- Libraries were prepared from antibody fragments (scFv, scFab, Fab) displayed on yeast or phage from peripheral blood mononuclear cells (PBMCs) from an HIV-1 infected individual. The libraries were panned and screened with a peptide containing the 2F5 epitope (see Fig. 1 , "QQE NEQELLELD- KWASLWN", as well as with gpl 40s. Antibodies were identified that bound specifically to the peptide, that binding being competed with 2F5. The M66 antibody neutralized four out of four tested isolates from clade B.
- VH germline variable heavy
- CDR heavy chain complementary determining region
- Another preferred antibody for use in the invention is a mAb having the variable heavy and variable light sequences as the M66.6 antibody set forth in Table 3. Details of the identification of the M66.6 antibody are provided in Example 3.
- either the intact antibody or fragment e.g., antigen binding fragment thereof can be used in the method of the present invention.
- exemplary functional fragments (regions) include scFv, Fv, Fab', Fab and F(ab') 2 fragments.
- Single chain antibodies can also be used. Techniques for preparing suitable fragments and single chain antibodies are well known in the art. (See, for example, USPs 5,855,866; 5,877,289; 5,965,132; 6,093,399; 6,261 ,535;
- the invention also includes variants of the antibodies (and fragments) disclosed herein, including variants that retain the binding properties of the antibodies (and fragments) specifically disclosed, and methods of using same in the present method.
- the invention includes an isolated human antibody or fragment thereof that binds selectively to gp41 MPER and that comprises one or more CDRs as set forth in Table 2 and Fig. 4.
- Modifications of M66 and M66.6 that can be used therapeutically in accordance with the invention include IgA, IgM and IgG l , 2, 3 or 4 versions of the M66 M66.6 VH and VL chains.
- compositions can comprise the antibody (or antibody fragment) dissolved or dispersed in a pharmaceutically acceptable carrier (e.g., an aqueous medium).
- a pharmaceutically acceptable carrier e.g., an aqueous medium.
- the compositions can be sterile and can in an injectable form.
- the antibodies (and fragments thereof) can also be formulated as a composition appropriate for topical administration to the skin or mucosa.
- Such compositions can take the form of liquids, ointments, creams, gels and pastes. Standard formulation techniques can be used in preparing suitable compositions.
- the antibodies can be formulated so as to be administered as a post-coital douche or with a condom.
- the antibodies and antibody fragments of the invention show their utility for prophylaxis in, for example, the following settings: i) in the setting of anticipated known exposure to HIV-1 infection, the antibodies described herein (or binding fragments thereof) can be administered prophylactically (e.g., IV or topically) as a microbiocide,
- the antibodies described herein in the setting of known or suspected exposure, such as occurs in the setting of rape victims, or commercial sex workers, or in any heterosexual transmission with out condom protection, can be administered as post-exposure prophylaxis, e.g., IV or topically,
- antibodies described herein in the setting of Acute HIV infection (AHI) can be administered as a treatment for AHI to control the initial viral load and preserve the CD4+ T cell pool and prevent CD4+ T cell destruction, and
- Suitable dose ranges can depend, for example, on the antibody and on the nature of the formulation and route of administration. Optimum doses can be determined by one skilled in the art without undue experimentation. Doses of antibodies in the range of 1 Ong to 20 ⁇ g ml can be suitable.
- the present invention provides a cell culture system that makes possible the production of monoclonal anti-viral antibodies from B-chronic lymphocytic leukemia (B-CLL) cell repertoires.
- B-CLL B-chronic lymphocytic leukemia
- macrophage cells are used as feeder cells to grow B-CLL cells in culture following EBV-infection.
- a protocol suitable for use in generating immortalized clones of B-CLL cells is set forth in Figure 8.
- a macrophage cell line e.g., a rodent macrophage cell line
- a preferred macrophage cell line is the mouse line J774A.1.
- J774A.1 macrophage cells have been shown to produce growth factors suitable for hybridoma growth and cloning (Rathjen and Geczy, Hybridoma 5:255-261 (1986)).
- Conditioned medium prepared from J774A.1 cells has been widely used for enhancing hybridoma viability.
- the macrophage cell line is subjected to irradiation to prevent outgrowth of the feeder cells.
- the optimum ⁇ -irradiation dose can be determined experimentally, for example, by testing the cell line to determine the minimum dose required to completely inhibit cell proliferation (e.g., about 4,000 Rad).
- the irradiated cells can then be distributed into culture containers (for example, when 96-well plates are used, about 50,000 cells can distributed/well (about 100 ⁇ /well)).
- the optimum number of irradiated cells can be determined experimentally by testing the cells at different densities.
- EBV infection of B-CLL cells can be effected using standard techniques.
- peripheral blood mononuclear cells PBMCs
- PBMCs peripheral blood mononuclear cells
- PS 2006 a Tolllike receptor 9 (TLR-9) agonist
- TLR-9 Tolllike receptor 9
- Cyclosporin A can be added to suppress any EBV-B cell-specific cytotoxic T cell response.
- Optimal concentrations can be determined
- an EBV suspension is then added to the cell suspension.
- the EBV-infected cells can be resuspended in complete medium comprising, for example, PS2006, distributed into the culture container with the irradiated macrophage cells and incubated at about 37°C.
- the medium can be changed periodically and antibody production assessed using, for example, ELISA when the EBV-infected cells have grown sufficiently (e.g., about 3-about 4 weeks post-infection).
- IgM producing hybridoma cell lines derived from CLL cells can then be produced, for example, using a hybridoma cell fusion method, such as that described in Fig. 10, and cloned.
- a hybridoma cell fusion method such as that described in Fig. 10, and cloned.
- Fig. 1 1 Three monoclonal B-CLL hybridoma cell lines have been derived from CLL246 (VH1 -69, unmutated case), CLL1075 (VH1 -69, mutated case), and CLL493 (VH1-69, unmutated case).
- Therapeutic antibodies e.g., anti-HIV antibodies, anti-hepatitis C antibodies or anti-influenza antibodies
- B-CLL cells immortalized in accordance with the method described above, or fragments thereof e.g., antigen binding fragments - exemplary functional fragments (regions) include scFv, Fv, Fab', Fab and F(ab') 2 fragments
- a composition e.g., a pharmaceutical composition
- Suitable compositions can comprise the antibody (or antibody fragment) dissolved or dispersed in a pharmaceutically acceptable carrier (e.g., an aqueous medium).
- the compositions can be sterile and can be in an injectable form.
- the antibodies (and fragments thereof) can also be formulated as a composition appropriate for topical administration to the skin or mucosa.
- Such compositions can take the form of liquids, ointments, creams, gels, pastes or aerosols. Standard formulation techniques can be used in preparing suitable compositions.
- anti-HIV antibodies and fragments thereof show their utility for prophylaxis in, for example, the following settings:
- the antibodies described herein can be administered prophylactically (e.g., IV or topically) as a microbiocide,
- the antibodies described herein in the setting of known or suspected exposure, such as occurs in the setting of rape victims, or commercial sex workers, or in any heterosexual transmission with out condom protection, can be administered as post-exposure prophylaxis, e.g., IV or topically,
- antibodies described herein in the setting of Acute HIV infection (AHI) can be administered as a treatment for AHI to control the initial viral load and preserve the CD4+ T cell pool and prevent CD4+ T cell destruction, and
- Anti-hepatitis C and anti -influenza antibodies, or fragments thereof as described above, can be used to treat or prevent hepatitis C and influenza infection, respectively.
- Suitable dose ranges can depend, for example, on the antibody, on the nature of the formulation, on the route of administration, and on the patient (e.g., a human patient). Optimum doses can be determined by one skilled in the art without undue experimentation. Doses of antibodies in the range of l Ong to 20 ⁇ g/ml can be suitable.
- IgM and IgG libraries from a patient with acute infection and a patient with 2F5-like antibodies were generated and analyzed by high throughput (454) sequencing and other methods.
- HIV- 1 -specific antibodies from IgG libraries derived from the blood of an acutely infected patient at two time points (40 days and 8 months) were identified. These antibodies bound envelope glycoproteins (Envs) with high affinity but did not neutralize a panel of 9 pseudo viruses.
- Antibodies from samples at 40 days were not found at 8 months and antibodies from samples at 8 months did not bind a dominant Env at 40 days. Panning of bone marrow derived libraries from the same patient did not result in selection of any antibodies.
- Novel antibodies were selected from IgM+IgG phage and yeast display libraries derived from a patient with 2F5-like antibodies.
- One of these antibodies, M66 has long (23 residues) heavy chain CDR3 and its VH gene has relatively low number of somatic mutations. It bound specifically to a gp41 MPER peptide containing the 2F5 epitope and cross-reactively neutralized HIV-1 isolates. The other antibodies are being characterized. These results could have implications for understanding humoral immune responses and design of vaccine immunogens. (See Figs. 1 and 2.)
- cDNA was prepared using the total RNA extracted from PBML taken from Patient SC44 at 12 month after enrollment (Shen et al, J. Virol. 83 :3617-25 (2009)). HIV-1 gp41 MAbs 2F5 was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIA1D, NIH (Hermann
- Phage display Fab libraries were constructed primarily following a published protocol (Zhu et al, Methods Mol. Biol. 525: 129-42, xv (2009)) using the cDNA prepared from PBMC of patient SC44 as template for the antibody gene repertoire cloning. Sequential pannings were performed using biotinylated Peptide SP62 and gpl40 proteins with the first three rounds of panning on ⁇ ig of biotinylated peptide on streptavidin conjugated magnetic bead and the fourth and fifth pannings on gpl 40 (JRFL) coated at l ug/well on 96 well ELISA plates. Bound phage on the beads or plate wells were directly used to infect
- the Fd fragment of m66 Fab construct was PCR amplified and fused with the light chain gene repertoire obtained during the original Fab library
- Antigens for capturing the biotinylated peptide or gpl40 were coated on narrow-well, 96-well plate at 50 ng/well in PBS overnight at 4°C.
- phage ELISA 10 10 phage from each round of panning was incubated with antigen. Bound phage was detected with anti-M13- HRP polyclonal antibody (Pharmacia, Piscataway, J).
- anti-Flag HRP conjugate was used to detect the binding.
- IgGl binding ELISA HRP conjugated goat anti-human IgG antibodies was used for detecting.
- Viruses pseudotyped with HIV-1 Envs were prepared by cotransfection of 70-80% confluent 293T cells with pNL4-3.luc.E-R- and pSV7d constructs encoding HIV-1 Envs (a gift from G. Quinnan, USUHS, Bethesda, MD) by using the PolyFect transfection reagent (Qiagen) according to manufacturer's
- Pseudotyped viruses were obtained after 24 h by centrifugation and filtration of cell culture through 0.45- ⁇ filters. For neutralization, viruses were mixed with different concentrations of antibodies for 1 h at 37 °C, and then the mixture was added to -1.5 ⁇ 10 4 HOS-CD4-CCR5 (used for all R5 and dual tropic viruses) or HOS-CD4-CXCR4 cells grown in each well of 96-well plates. Luminesence was measured after 48 h by using the Bright-Glo Luciferase Assay System (Promega, Madison, WI) and a LumiCount microplate luminometer (Turner Designs). Mean relative light units (RLU) for duplicate wells were determined. Percentage inhibition was calculated by the following formula: (1 - average RLU of antibody-containing wells/average RLU of virus-only wells) ⁇ 100.
- Neutralization of HIV-1 in the PBMC assay was measured as a reduction in LucR reporter gene expression after multiple rounds of virus replication.
- Virus was incubated with serial 3-fold dilutions of test sample (eight dilutions total) in duplicate in a total volume of 150 ⁇ of IL-2-containing growth medium for 1 h at 37°C in a 96-well U-bottom culture plate.
- One-day-old PHA-PBMCs (2 ⁇ 10 5 cells in 50 ⁇ of IL-2 -containing growth medium) were added to each well.
- One set of control wells received cells plus virus (virus control) and another set received cells only (background control).
- TZM bl cells and TZM-bl cells expressing FcyRI based pseudovirus neutralization assay was previously described in Perez et al (J. Virol.
- IgG-derived Fd fragments were PCR amplified by using the cDNA isolated from the patient as a template.
- the sense primers used were described previously (Zhu et al, Methods Mol. Biol. 525: 129-42, xv (2009)); the antisense primer was IgGR (5'-
- the PCR was performed in a volume of 50 ⁇ for 25 cycles.
- the products were gel-purified and then used as a template for additional 12 cycles of secondary PCR amplification with primers (HF12: 5'- CCATCTCATCCCTGCGTGTCTCCGACTCAGTACTGAGCTAGCTGCCCA ACCAGCCATGGCC-3 ' and HR2:
- m66 VH is derived from VH51 -1 V gene, there are 8 mutations in the heavy chain V gene segment; m66VL is derived from VK-1 -39 , there are 3 mutation in the light chain V gene segment.
- m66 VH and VL bear a significantly lower number of mutations from their germline predecessors, which might indicate m66 is still in the early stage of the antibody maturation process. It was observed that the heavy chain CDR3 has 23 residues with multiple tyrosines and one phenylalanine.
- light chain shuffling library with size at 2x10 was constructed as described above.
- a chain shuffling library was panned two rounds against MPER peptide followed by Phage ELISA screening using g l40 protein as target.
- Six unique clones were identified which share the same heavy chain as expected but paired with different light chains with several mutations from the same VL subfamily. ELISA data showed they all bind similarly well to both the peptide and gpl40 (data not shown).
- one which has 9 mutations in the light chain V gene segment was designated as m66.6 and converted to IgG l for further characterization. Specific binding of m66 to both MPER peptide and gpl40
- m66.6 and 2F5 IgGl s bind equally well to both the MPER peptide and JRFL gpl40 protein, overall, the neutralization potency of m66.6 is less than that of 2F5 in this set of neutralization assay.
- ' Values are the concentration ( ⁇ g/ml) at which relative luminescence units (RLUs) were reduced 50% compared to virus control wells (no test sample).
- VH germline gene segments from each of 7 VH subfamilies namely VH 1 -69, VH2-5, VH3-23, VH4-1 , VH51 -1 , VH6- 1 and VH7-l were used as probes to do similarity search against the whole VH gene repertoire. All the sequences from each search were ranked according to the similarity to the probes and were plotted against the similarity percentages and 7 probes as shown in Fig. 6. It was found that VH51 -1 derived genes were disproportionally expanded in this repertoire at the specific time point when the blood sample was taken in this patient.
- J774A.1 feeder cells enhance growth and production of IgM from B-CLL cells (CLL246) after Epstein Barr virus (EBV) infection. After incubation with EBV, the B-CLL cells were plated at 5,000 cells/well (A) in the absence of J774A.1 cells or (B) in the presence of irradiated J774A.1 cells (50,000 cells/well). Three weeks after infection, levels of IgM were detected by ELISA and expressed in ⁇ g ml.
- the CLL246 cells produce IgM against both HIV-1 gpl40 and hepatitis virus C E2 (HCV E2) envelope proteins. IgM against the test antigens was detected by ELISA and expressed in OD. (See also Fig. 16.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10817555A EP2477658A2 (fr) | 2009-09-16 | 2010-09-16 | Anticorps anti-vih-1 |
CA2774446A CA2774446A1 (fr) | 2009-09-16 | 2010-09-16 | Anticorps anti-vih-1 |
JP2012529742A JP2013505236A (ja) | 2009-09-16 | 2010-09-16 | Hiv−1抗体 |
AU2010296058A AU2010296058A1 (en) | 2009-09-16 | 2010-09-16 | HIV-1 antibodies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27234909P | 2009-09-16 | 2009-09-16 | |
US61/272,349 | 2009-09-16 | ||
US24879609P | 2009-10-05 | 2009-10-05 | |
US61/248,796 | 2009-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011034582A2 true WO2011034582A2 (fr) | 2011-03-24 |
WO2011034582A3 WO2011034582A3 (fr) | 2011-09-15 |
Family
ID=43759219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/002515 WO2011034582A2 (fr) | 2009-09-16 | 2010-09-16 | Anticorps anti-vih-1 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2477658A2 (fr) |
JP (1) | JP2013505236A (fr) |
AU (1) | AU2010296058A1 (fr) |
CA (1) | CA2774446A1 (fr) |
WO (1) | WO2011034582A2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3271022A4 (fr) * | 2015-03-19 | 2018-10-31 | Duke University | Anticorps neutralisant le vih-1 et leurs utilisations |
WO2020010107A1 (fr) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
WO2021011544A1 (fr) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Vaccins contre le vih et leurs procédés de fabrication et d'utilisation |
US11071783B2 (en) | 2015-03-19 | 2021-07-27 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
WO2022046644A1 (fr) | 2020-08-25 | 2022-03-03 | Gilead Sciences, Inc. | Molécules de liaison à un antigène multi-spécifiques ciblant le vih et méthodes d'utilisation |
WO2022087149A2 (fr) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation |
WO2024015741A1 (fr) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci |
WO2024097957A1 (fr) * | 2022-11-03 | 2024-05-10 | Duke University | Nouveaux anticorps contre le vih et leurs procédés de fabrication et d'utilisation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020081723A1 (en) * | 1995-06-07 | 2002-06-27 | Peter Brams | Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
WO2006110831A2 (fr) * | 2005-04-12 | 2006-10-19 | Duke University | Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine |
-
2010
- 2010-09-16 JP JP2012529742A patent/JP2013505236A/ja not_active Ceased
- 2010-09-16 EP EP10817555A patent/EP2477658A2/fr not_active Withdrawn
- 2010-09-16 AU AU2010296058A patent/AU2010296058A1/en not_active Abandoned
- 2010-09-16 CA CA2774446A patent/CA2774446A1/fr active Pending
- 2010-09-16 WO PCT/US2010/002515 patent/WO2011034582A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020081723A1 (en) * | 1995-06-07 | 2002-06-27 | Peter Brams | Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture and theraputic use thereof |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
WO2006110831A2 (fr) * | 2005-04-12 | 2006-10-19 | Duke University | Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine |
Non-Patent Citations (2)
Title |
---|
VIDAR WENDEL-HANSEN ET AL.: 'Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines.' LEUKEMIA vol. 8, no. 3, 1994, pages 476 - 484, XP008154323 * |
XIAOYING SHEN ET AL.: 'In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.' JOURNAL OF VIROLOGY vol. 83, no. 8, April 2009, pages 3617 - 3625, XP008154322 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3271022A4 (fr) * | 2015-03-19 | 2018-10-31 | Duke University | Anticorps neutralisant le vih-1 et leurs utilisations |
US11071783B2 (en) | 2015-03-19 | 2021-07-27 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
AU2016232693B2 (en) * | 2015-03-19 | 2021-08-12 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
US11944681B2 (en) | 2015-03-19 | 2024-04-02 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
WO2020010107A1 (fr) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
EP4257600A2 (fr) | 2018-07-03 | 2023-10-11 | Gilead Sciences, Inc. | Anticorps se liant spécifiquement à la gp120 du vih pd-1 et leurs methodes d'utilisation |
WO2021011544A1 (fr) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Vaccins contre le vih et leurs procédés de fabrication et d'utilisation |
WO2022046644A1 (fr) | 2020-08-25 | 2022-03-03 | Gilead Sciences, Inc. | Molécules de liaison à un antigène multi-spécifiques ciblant le vih et méthodes d'utilisation |
WO2022087149A2 (fr) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation |
WO2024015741A1 (fr) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci |
WO2024097957A1 (fr) * | 2022-11-03 | 2024-05-10 | Duke University | Nouveaux anticorps contre le vih et leurs procédés de fabrication et d'utilisation |
Also Published As
Publication number | Publication date |
---|---|
JP2013505236A (ja) | 2013-02-14 |
AU2010296058A1 (en) | 2012-05-03 |
CA2774446A1 (fr) | 2011-03-24 |
EP2477658A2 (fr) | 2012-07-25 |
WO2011034582A3 (fr) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120269821A1 (en) | Hiv-1 antibodies | |
McCoy et al. | Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization | |
Tudor et al. | HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis | |
WO2011034582A2 (fr) | Anticorps anti-vih-1 | |
Xiao et al. | Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | |
CN102272158B (zh) | 源自记忆b细胞的人单克隆抗体的快速表达克隆 | |
WO2016149710A2 (fr) | Anticorps neutralisant le vih-1 et leurs utilisations | |
EP2788026A2 (fr) | Immunogènes v1v2 | |
Choudhry et al. | Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies | |
US20070292390A1 (en) | Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies | |
US20150252099A1 (en) | High affinity human antibodies to human cytomegalovirus (cmv) gb protein | |
WO2011092593A2 (fr) | Anticorps neutralisant le vih-1 et leurs utilisations | |
EP3110844B1 (fr) | Anticorps monoclonaux neutralisants à large spectre contre la région v1v2 env du vih-1 | |
Sun et al. | Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies | |
CN110483636B (zh) | 人源抗HIVgp120特异性抗体Z166及其应用方法 | |
EP0577243A2 (fr) | Anticorps monoclonaux recombinants, neutralisant le HIV pour la prévention et traitement des infections du HIV | |
Dorgham et al. | Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes | |
Yang et al. | Identification of non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies | |
Yuan et al. | Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development | |
CN107383190B (zh) | 人源抗HIV gp41特异性抗体及其应用 | |
Houimel et al. | Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library | |
WO2018053328A1 (fr) | Molécules bispécifiques comprenant un bras ciblant l'enveloppe du vih-1 | |
Wrotniak et al. | Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2 | |
Li et al. | N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies | |
US20240228595A1 (en) | Methods for Monoclonal Antibody Generation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10817555 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012529742 Country of ref document: JP Ref document number: 2774446 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010817555 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010296058 Country of ref document: AU |
|
ENP | Entry into the national phase in: |
Ref document number: 2010296058 Country of ref document: AU Date of ref document: 20100916 Kind code of ref document: A |